Novel Method to Design Better Antibiotics Established at the CHOP

A new study describes a novel approach for developing new antibiotics. The researchers developed a structure-guided design to create prodrugs that act as a "Trojan Horse," allowing antibiotics to reach resistant bacteria. The work paves the way for structure-guided development of S. aureus-specific prodrugs and establishes a pipeline for the identification of additional prodrug activating enzymes.

Merck & Co. to Acquire Acceleron for $11.5B

Acceleron's lead therapeutic candidate, sotatercept, is a reverse-remodeling agent designed to rebalance TGF-beta superfamily signaling. Sotatercept is in Phase III studies as an add-on to current standard of care for the treatment of PAH, as well as in a Phase II trial in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Sotatercept met its primary endpoint of improvement in pulmonary vascular resistance in PAH patients in an earlier Phase II trial.

ProtAffin Receives €2.1M Austrian Grant to Take IL-8 Decoy into Clinic

Lead anti-inflammatory candidate PA401 stops native IL-8 from glycan binding and neutrophil activation.

Applikon Biotechnology: Joins the Race to Develop a COVID-19 Vaccine

Since the beginning of March, Applikon Biotechnology has been working with the Laboratory of Virology and the Bioprocess Engineering Group of Wageningen University on the development of a COVID-19 vaccine, based on mimicking the virus’s “spike protein.

iThemba Pharmaceuticals and Pyxis Discovery to Commingle Service Offerings

iThemba Pharmaceuticals' service division and Pyxis Discovery signed a collaborative agreement to jointly market each other’s services. Pyxis' computational chemistry and lead discovery expertise...

Small Molecule Cancer Inhibitors May Suppress Growth in Some Drug Resistant...

City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance. Their study provides new insight into how cancer stem cells replenish and visibility into how cancer evades our immune system.

Machine Learning Helps Optimize Therapeutic Antibodies

Researchers have developed a machine learning method to support the time-intensive and resource-demanding process of optimizing antibody therapeutics. The method predicts antigen specificity from antibody sequence via deep learning. In this study, the researchers provide a proof of concept for their new method using Roche's antibody cancer drug Herceptin. Now, they are applying their AI method to optimize antibody drugs that are in clinical development.

BridgeBio, Helsinn Ink Up-to-$2.4B Infigratinib Partnership

The collaboration comes as the FDA is reviewing an NDA for infigratinib in patients with previously treated, FGFR-mutant cholangiocarcinoma (bile duct cancer).

Takeda Joins ImmunoGen to Co-Develop Cancer ADCs in $440M+ Partnership

Companies agree to commercialize targeted anti-cancer treatments for up to two undisclosed targets

Synthetic Biology Technique Used to Produce Novel Antibiotic

Researchers developed a new genetic platform that allows efficient production of naturally occurring molecules and used it to produce a novel antibiotic compound.